Dosimetry, pharmacokinetics, and tumor and immune responses will also be assessed for [Lu-177]-PNT6555, as well as safety, tolerability, and diagnostic performance of [Ga-68]-PNT6555 PET/CT. Key eligibility criteria include being refractory to prior treatment with no alternative available ...
Ten met all eligibility criteria and received at least one cycle of [Lu-177]-PNT6555, including two with STS, three with CRC, three with PDAC, and one each with CCA and esophageal cancer. Of these ten, two received two cycles, two received three cycles, and no participants received four...